» Articles » PMID: 35942853

Duration of Antibiotic Therapy in Gram-negative Infections with a Particular Focus on Multidrug-resistant Pathogens

Overview
Date 2022 Aug 9
PMID 35942853
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Antimicrobial overuse is a major health problem that contributes to antimicrobial resistance (AMR). Infections with Gram-negative bacilli (GNB) and multidrug-resistant organisms (MDRs) are associated with high morbidity and mortality, particularly in patients with underlying medical conditions.

Recent Findings: Although many recent studies have been published about the novel antibiotics in treating infections including those due to MDR-GNB, the optimal duration of treatment (DOT) remains inconclusive. Recent observation has supported that short antibiotic therapy (SAT) decreases AMR and adverse effects. This narrative review provides an overview of the most recent published studies on the duration of therapy in the treatment of GNB infections, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), intra-abdominal infections (IAIs), bloodstream infections (BSIs) and urinary tract infections (UTIs), with a particular focus on MDR-GNB.

Summary: Studies showed different outcomes when comparing SAT to long antimicrobial therapy (LAT). No generalization can be made on all sites of infections and different GNBs. Further studies are needed to address the optimal DOT in MDR-GNB, as this group is underrepresented in recent studies.

Citing Articles

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial.

Arns B, Kalil A, Sorio G, Boschi E, Antonio A, Antonio J Crit Care. 2024; 28(1):412.

PMID: 39695798 PMC: 11653996. DOI: 10.1186/s13054-024-05178-6.


Navigating antibiotic therapy in acute cholangitis: Best practices and new insights.

Masuda S, Imamura Y, Jinushi R, Kimura K, Ryozawa S, Koizumi K J Hepatobiliary Pancreat Sci. 2024; 32(1):44-57.

PMID: 39537571 PMC: 11780307. DOI: 10.1002/jhbp.12087.


Exploring the effects of short-course antibiotics on children's gut microbiota by using 16S rRNA gene sequencing: a case-control study.

Zhou Y, Chen X, Wang T, Huang R BMC Pediatr. 2024; 24(1):562.

PMID: 39232719 PMC: 11373496. DOI: 10.1186/s12887-024-05042-0.


Association of short-course antimicrobial therapy and bacterial resistance in acute cholangitis: Retrospective cohort study.

Masuda S, Jinushi R, Imamura Y, Kubota J, Kimura K, Shionoya K Endosc Int Open. 2024; 12(2):E307-E316.

PMID: 38420157 PMC: 10901644. DOI: 10.1055/a-2230-8229.


A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol.

Arns B, Horvath J, Rech G, Sesin G, Agani C, da Rosa B Infect Dis Ther. 2023; 13(1):237-250.

PMID: 38102448 PMC: 10828314. DOI: 10.1007/s40121-023-00897-9.